News
3 No-Brainer Stocks to Buy for Under $100 Right Now
You don't need much money to get started investing. And stocks with relatively low share prices have tremendous growth prospects.
Three Fool.com contributors identified no-brainer healthcare stocks
Why Pfizer Stock Slipped by 2% Today
On the surface, Pfizer (NYSE: PFE) had some good news to report on Thursday. But investors viewed the positive as a negative, in light of its timing. This wasn't helped by an analyst's price-target
Can Pfizer Stock Double Your Money in 3 Years?
Pfizer (NYSE: PFE) has been a losing play for investors over the past 12 months. To wit: The drugmaker's stock has fallen by a whopping 28.8% over this period. Part of that decline has been driven
Got $5,000? These 3 Industry Stalwarts Are Trading Near Their 52-Week Lows
A good way to diversify your portfolio is to invest in companies in different industries. And if you want to minimize your risk, a good option is to consider investing in industry leaders. Their
Why Novo Nordisk Stock Is Falling Today
Shares of the Danish pharma giant Novo Nordisk (NYSE: NVO) were down by 3.4% on elevated volume as of 1:14 p.m. ET Tuesday afternoon. The drugmaker's shares are falling in response to the strong
Why Pfizer Stock Crushed the Market on Monday
Investors flocked to Pfizer (NYSE: PFE) stock on Monday following some highly encouraging news about one of the company's pipeline drugs. The holy grail of pharmaceutical companies and biotechs is
Pfizer Just Took Out $31 Billion in Debt. Here's Why That's Good News
On May 16, Pfizer (NYSE: PFE) announced that it was going to take out $31 billion in fresh debt to pay for its purchase of Seagen (NASDAQ: SGEN), an oncology drug developer. In total, it'll pay $43
Should Income Investors Buy This Big Pharma Stock?
Amid the start of the COVID-19 pandemic, big pharma companies like Pfizer (NYSE: PFE) began expedited clinical trials of COVID-19 vaccines and antiviral treatments. And a combination of incredible
Which Is the Better Forever Stock: Johnson & Johnson or UnitedHealth Group?
Johnson & Johnson (NYSE: JNJ) and UnitedHealth Group (NYSE: UNH) are considered great healthcare stocks to hold for the long term because of their size, steady cash flow, and above-average
Vaccine Sales Are Falling. Should You Still Buy Pfizer?
Pfizer (NYSE:PFE) confirmed this week what everyone has been expecting. COVID-19 vaccine sales are falling drastically. The company reported a 77% drop in Comirnaty sales in the first quarter
3 Top Healthcare Stocks to Buy in May
Healthcare stocks always make a great addition to long-term portfolios. They offer you the potential to benefit from steady earnings growth over time. After all, regardless of the economic
Is This Incredibly Cheap, High-Yield Dividend Stock a Screaming Buy After Q1 Earnings?
High-quality dividend stocks are normally a great addition to any portfolio regardless of market conditions. However, this exceedingly risk-averse market has punished even elite dividend-paying
3 of the Best Growth Stocks to Buy in May
The bull market hasn't arrived yet, but when it does, growth stocks could be hot buys again. Three growing businesses stand out to me as good buys for investors to consider right now: UnitedHealth
Why Pfizer Is Among the Best High-Yield Dividend Stocks on the Market Now
Some income investors might view Pfizer (NYSE: PFE) stock as a falling knife to be avoided. After all, the big drugmaker's share price has already plunged more than 20% so far this year. Pfizer just
2 Unstoppable Growth Stocks to Buy While Share Prices Are Low
A look at the facts will often reveal businesses that are poised for future growth and/or show no signs of slowing down. The stocks for these types of businesses tend to be particularly valuable to
Which Healthcare Company Will Be the First to Get to a $1 Trillion Market Cap?
There are several healthcare companies with market caps in the hundreds of billions. However, there isn't one among this group that is approaching the $1 trillion mark just yet. There are four
European Commission Approves Pfizer’s DURVEQTIX® (fidanacogene elaparvovec), a One-Time Gene Therapy for Adults with Hemophilia B
Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has granted conditional marketing authorization for DURVEQTIX® (fidanacogene elaparvovec), a gene therapy for the treatment
Pfizer Announces Positive Topline Results From Phase 3 Study of Hemophilia A Gene Therapy Candidate
Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 AFFINE study (NCT04370054) evaluating giroctocogene fitelparvovec, an investigational gene therapy for the
Pfizer Advances Development of Once-Daily Formulation of Oral GLP-1 Receptor Agonist Danuglipron
Pfizer Inc. (NYSE: PFE) today announced that based on results from the ongoing pharmacokinetic study (NCT06153758), the company has selected its preferred once-daily modified release formulation
Pfizer to Launch Process to Identify a Successor for Dr. Mikael Dolsten, Chief Scientific Officer and President, Pfizer Research & Development
Pfizer Inc. (NYSE: PFE) today announced that the company is launching the process to identify a successor for Dr. Mikael Dolsten, Pfizer’s Chief Scientific Officer and President, Pfizer Research &
Cyrus Taraporevala Elected to Pfizer’s Board of Directors
Pfizer Inc. (NYSE: PFE) today announced the election of Cyrus Taraporevala to its Board of Directors, effective immediately. Mr. Taraporevala, age 57, was also appointed to and will join the Audit
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union
Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)
Pfizer Declares Third-Quarter 2024 Dividend
Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.42 third-quarter 2024 dividend on the company’s common stock, payable September 3, 2024, to holders of the Common
Pfizer Invites Public to View and Listen to Webcast of July 30 Conference Call with Analysts
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:30 a.m. EDT on Tuesday, July 30, 2024. The
ELREXFIO™ Shows Median Overall Survival of More Than Two Years in People with Relapsed or Refractory Multiple Myeloma
Pfizer Inc. (NYSE: PFE) today announced detailed overall survival (OS) results from the Phase 2 MagnetisMM-3 study of ELREXFIO™ (elranatamab-bcmm) in patients with heavily pretreated relapsed or